Revolution Medicines Posts Positive Phase 1/2 Zoldonrasib Data in Metastatic Pancreatic Cancer, Backing Phase 3 Trials
Updated
Updated · Simply Wall St · Jul 6
Revolution Medicines Posts Positive Phase 1/2 Zoldonrasib Data in Metastatic Pancreatic Cancer, Backing Phase 3 Trials
3 articles · Updated · Simply Wall St · Jul 6
Summary
Phase 1/2 results showed zoldonrasib combinations delivered high response and disease-control rates with manageable safety in metastatic pancreatic ductal adenocarcinoma, giving Revolution Medicines an early clinical boost in a hard-to-treat cancer.
The oral RAS(ON) G12D inhibitor was tested with standard chemotherapy or with daraxonrasib, supporting the company’s strategy of targeting a mutation that currently has no approved targeted therapies.
June already marked the start of patient treatment in RASolute 305, a global Phase 3 trial of zoldonrasib plus standard chemotherapy in first-line RAS G12D metastatic pancreatic cancer; the new data also support planned RASolute 309 studies.
The update sharpens focus on execution risk as Revolution Medicines pushes large late-stage programs while managing heavy R&D spending, even as the mutation affects tens of thousands of new U.S. cancer patients each year.
Has Revolution Medicines cracked the code on 'undruggable' cancer, or is a new challenge of drug resistance just beginning?
With a $40B valuation fueled by hope, can this biotech's breakthrough data translate into profit before its cash runs out?
Zoldonrasib Achieves 82% Response Rate in First-Line Pancreatic Cancer: Revolution Medicines’ Breakthrough Against KRAS G12D
Overview
Revolution Medicines is generating significant optimism with its investigational drug, zoldonrasib, which is emerging as a new hope for patients with pancreatic cancer, especially those with the difficult RAS G12D mutation. The company’s RAS inhibitor pipeline has shown additional wins in pancreatic cancer trials, signaling a promising shift in treatment. Pancreatic ductal adenocarcinoma remains one of the most aggressive cancers, with a major unmet need for effective therapies. Zoldonrasib is designed to specifically block oncogenic variants and aims to halt the growth of diverse tumor cells, offering renewed hope for patients facing limited options.